Pharming (genetics) Article

From Wikipedia, the free encyclopedia
  (Redirected from Molecular farming)
Jump to navigation Jump to search

Pharming, a portmanteau of "farming" and " pharmaceutical", refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). [1] [2] Pharming is also known as molecular farming, molecular pharming [3] or biopharming. [4]

The products of pharming are recombinant proteins or their metabolic products. Recombinant proteins are most commonly produced using bacteria or yeast in a bioreactor, but pharming offers the advantage to the producer that it does not require expensive infrastructure, and production capacity can be quickly scaled to meet demand, at greatly reduced cost. [5]

History

THowever, in late 2002, just as ProdiGene was ramping up production of trypsin for commercial launch [6] it was discovered that volunteer plants (left over from the prior harvest) of one of their GM corn products were harvested with the conventional soybean crop later planted in that field. [7] ProdiGene was fined $250,000 and ordered by the USDA to pay over $3 million in cleanup costs. This raised a furor and set the pharming field back, dramatically. [5] Many companies went bankrupt as companies faced difficulties getting permits for field trials and investors fled. [5] In reaction, APHIS introduced more strict regulations for pharming field trials in the US in 2003. [8] In 2005, Anheuser-Busch threatened to boycott rice grown in Missouri because of plans by Ventria Bioscience to grow pharm rice in the state. A compromise was reached, but Ventria withdrew its permit to plant in Missouri due to unrelated circumstances.

The industry has slowly recovered, by focusing on pharming in simple plants grown in bioreactors and on growing GM crops in greenhouses. [9] Some companies and academic groups have continued with open-field trials of GM crops that produce drugs. In 2006 Dow AgroSciences received USDA approval to market a vaccine for poultry against Newcastle disease, produced in plant cell culture – the first plant-produced vaccine approved in the U.S. [10] [11]

In mammals

Historical development

Milk is presently the most mature system to produce recombinant proteins from transgenic organisms. Blood, egg white, seminal plasma, and urine are other theoretically possible systems, but all have drawbacks. Blood, for instance, as of 2012 cannot store high levels of stable recombinant proteins, and biologically active proteins in blood may alter the health of the animals. [12] Expression in the milk of a mammal, such as a cow, sheep, or goat, is a common application, as milk production is plentiful and purification from milk is relatively easy. Hamsters and rabbits have also been used in preliminary studies because of their faster breeding.

One approach to this technology is the creation of a transgenic mammal that can produce the biopharmaceutical in its milk (or blood or urine). Once an animal is produced, typically using the pronuclear microinjection method, it becomes efficacious to use cloning technology to create additional offspring that carry the favorable modified genome. [13] In February 2009 the US FDA granted marketing approval for the first drug to be produced in genetically modified livestock. [14] The drug is called ATryn, which is antithrombin protein purified from the milk of genetically modified goats. Marketing permission was granted by the European Medicines Agency in August 2006. [15]

Patentability issues

As indicated above, some mammals typically used for food production (such as goats, sheep, pigs, and cows) have been modified to produce non-food products, a practice sometimes called pharming. Use of genetically modified goats has been approved by the FDA and EMA to produce ATryn, i.e. recombinant antithrombin, an anticoagulant protein drug. [16] These products "produced by turning animals into drug-manufacturing 'machines' by genetically modifying them" are sometimes termed biopharmaceuticals.

The patentability of such biopharmaceuticals and their process of manufacture is uncertain. Probably, the biopharmaceuticals themselves so made are unpatentable, assuming that they are chemically identical to the preexisting drugs that they imitate. Several 19th century United States Supreme Court decisions hold that a previously known natural product manufactured by artificial means cannot be patented. [17] An argument can be made for the patentability of the process for manufacturing a biopharmaceutical, however, because genetically modifying animals so that they will produce the drug is dissimilar to previous methods of manufacture; moreover, one Supreme Court decision seems to hold open that possibility. [18]

On the other hand, it has been suggested that the recent Supreme Court decision in Mayo v. Prometheus [19] may create a problem in that, in accordance with the ruling in that case, "it may be said that such and such genes manufacture this protein in the same way they always did in a mammal, they produce the same product, and the genetic modification technology used is conventional, so that the steps of the process 'add nothing to the laws of nature that is not already present. [20] If the argument prevailed in court, the process would also be ineligible for patent protection. This issue has not yet been decided in the courts.

In plants

Plant-made pharmaceuticals (PMPs), also referred to as pharming, is a sub-sector of the biotechnology industry that involves the process of genetically engineering plants so that they can produce certain types of therapeutically important proteins and associated molecules such as peptides and secondary metabolites. The proteins and molecules can then be harvested and used to produce pharmaceuticals. [3]

Arabidopsis is often used as a model organism to study gene expression in plants, while actual production may be carried out in maize, rice, potatoes, tobacco, flax or safflower [21]. Tobacco has been a highly popular choice of organism for the expression of transgenes, as it is is easily transformed, produces abundant tissues, and survives well in vitro and in greenhouses. [22] The advantage of rice and flax is that they are self-pollinating, and thus gene flow issues (see below) are avoided. However, human error could still result in pharm crops entering the food supply. Using a minor crop such as safflower or tobacco, avoids the greater political pressures and risk to the food supply involved with using staple crops such as beans or rice. Expression of proteins in plant cell or hairy root cultures also minimizes risk of gene transfer, but at a higher cost of production. Sterile hybrids may also be used for the bioconfinement of transgenic plants, although stable lines can't be established. [23] Grain crops are sometimes chosen for pharming because protein products targeted to the endosperm of cereals have been shown to have high heat stability. This characteristic makes them an appealing target for the production of edible vaccines, as viral coat proteins stored in grains do not require cold storage the way many vaccines currently do. Maintaining a temperature controlled supply chain of vaccines is often difficult when delivering vaccines to developing countries. [24]

Most commonly, plant transformation is carried out using Agrobacterium tumefaciens. The protein of interest is often expressed under the control of the cauliflower mosaic virus 35S promoter ( CaMV35S), a powerful constitutive promoter for driving expression in plants. [25] Localization signals may be attached to the protein of interest to cause accumulation to occur in a specific sub-cellular location, such as chloroplasts or vacuoles. This is done in order to improve yields, simplify purification, or so that the protein folds properly. [26] [27] Recently, the inclusion of antisense genes in expression cassettes has been shown to have potential for improving the plant pharming process. Researchers in Japan transformed rice with an antisense SPK gene, which disrupts starch accumulation in rice seeds, so that products would accumulate in a watery sap that is easier to purify. [28]

Recently, several non-crop plants such as the duckweed Lemna minor or the moss Physcomitrella patens have shown to be useful for the production of biopharmaceuticals. These frugal organisms can be cultivated in bioreactors (as opposed to being grown in fields), secrete the transformed proteins into the growth medium and, thus, substantially reduce the burden of protein purification in preparing recombinant proteins for medical use. [29] [30] [31] In addition, both species can be engineered to cause secretion of proteins with human patterns of glycosylation, an improvement over conventional plant gene-expression systems. [32] [33] Biolex Therapeutics developed a duckweed-based expression platform; it sold that business to Synthon and declared bankruptcy in 2012.[ citation needed]

Additionally, an Israeli company, Protalix, has developed a method to produce therapeutics in cultured transgenic carrot or tobacco cells. [34] Protalix and its partner, Pfizer, received FDA approval to market its drug, taliglucerase alfa (Elelyso), treatment for Gaucher's disease, in 2012. [35]

Regulation

The regulation of genetic engineering concerns the approaches taken by governments to assess and manage the risks associated with the development and release of genetically modified crops. There are differences in the regulation of GM crops – including those used for pharming – between countries, with some of the most marked differences occurring between the USA and Europe. Regulation varies in a given country depending on the intended use of the products of the genetic engineering. For example, a crop not intended for food use is generally not reviewed by authorities responsible for food safety.

Controversy

There are controversies around GMOs generally on several levels, including whether making them is ethical, issues concerning intellectual property and market dynamics; environmental effects of GM crops; and GM crops' role in industrial agricultural more generally. There are also specific controversies around pharming.

Advantages

Plants do not carry pathogens that might be dangerous to human health. Additionally, on the level of pharmacologically active proteins, there are no proteins in plants that are similar to human proteins. On the other hand, plants are still sufficiently closely related to animals and humans that they are able to correctly process and configure both animal and human proteins. Their seeds and fruits also provide sterile packaging containers for the valuable therapeutics and guarantee a certain storage life. [36]

Global demand for pharmaceuticals is at unprecedented levels. Expanding the existing microbial systems, although feasible for some therapeutic products, is not a satisfactory option on several grounds. [37] Many proteins of interest are too complex to be made by microbial systems or by protein synthesis. [38] [36] These proteins are currently being produced in animal cell cultures, but the resulting product is often prohibitively expensive for many patients. For these reasons, science has been exploring other options for producing proteins of therapeutic value. [2] [37] [11]

These pharmaceutical crops could become extremely beneficial in developing countries. The World Health Organization estimates that nearly 3 million people die each year from vaccine preventable disease, mostly in Africa. Diseases such as measles and hepatitis lead to deaths in countries where the people cannot afford the high costs of vaccines, but pharm crops could help solve this problem. [39]

Disadvantages

While molecular farming is one application of genetic engineering, there are concerns that are unique to it. In the case of genetically modified (GM) foods, concerns focus on the safety of the food for human consumption. In response, it has been argued that the genes that enhance a crop in some way, such as drought resistance or pesticide resistance, are not believed to affect the food itself. Other GM foods in development, such as fruits designed to ripen faster or grow larger, are believed not to affect humans any differently from non-GM varieties. [2] [11] [36] [40]

In contrast, molecular farming is not intended for crops destined for the food chain. It produces plants that contain physiologically active compounds that accumulate in the plant’s tissues. Considerable attention is focused, therefore, on the restraint and caution necessary to protect both consumer health and environmental biodiversity. [2]

The fact that the plants are used to produce drugs alarms activists. They worry that once production begins, the altered plants might find their way into the food supply or cross-pollinate with conventional, non-GM crops. [40] These concerns have historical validation from the ProdiGene incident, and from the StarLink incident, in which GMO corn accidentally ended up in commercial food products. Activists also are concerned about the power of business. According to the Canadian Food Inspection Agency, in a recent report, says that U.S. demand alone for biotech pharmaceuticals is expanding at 13 percent annually and to reach a market value of $28.6 billion in 2004. [40] Pharming is expected to be worth $100 billion globally by 2020. [41]

List of originators (companies and universities), research projects and products

Please note that this list is by no means exhaustive.

  • Dow AgroSciences – poultry vaccine against Newcastle disease virus (first PMP to be approved for marketing by the USDA Center for Veterinary Biologics [42] Dow never intended to market the vaccine. [43] "'Dow Agrosciences used the animal vaccine as an example to completely run through the process. A new platform needs to be approved, which can be difficult when authorities get in contact with it for the first time', explains the plant physiologist Stefan Schillberg, head of the Molecular Biology Division at the Fraunhofer Institute for Molecular Biology and Applied Ecology Aachen." [44]
  • Fraunhofer Institute for Molecular Biology and Applied Ecology, with sites in Germany, the US, and Chile [45] is the lead institute of the Pharma Planta consortium of 33 partner organizations from 12 European countries and South Africa, funded by the European Commission. [46] Pharma Planta is developing systems for plant production of proteins in greenhouses in the European regulatory framework. [47] It is collaborating on biosimilars with Plantform and PharmaPraxis (see below). [48]
  • Genzymeantithrombin III in goat milk
  • GTC Biotherapeutics – ATryn (recombinant human antithrombin) in goat milk [49]
  • Icon Genetics produces therapeutics in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses in Halle, Germany [50] [51] or in fields. First product is a vaccine for a cancer, non-Hodgkin's lymphoma. [51]
  • Iowa State University – immunogenic protein from E. coli bacteria in pollen-free corn as a potential vaccine against E. coli for animals and humans [52] [53] [54]
  • Kentucky Bioprocessing took over Large Scale Biology's facilities in Owensboro, Kentucky, and offers contract biomanufacturing services in tobacco plants, grown in greenhouses or in open fields. [55]
  • Medicago Inc. – Pre-clinical trials of Influenza vaccine made in transiently infected Nicotiana benthamiana (relative of tobacco) plants in greenhouses [56] Medicago has a system for pharming in alfalfa that their website says is "not suited for the production of vaccines" [57]
  • PharmaPraxis – Developing biosimilars in collaboration with PlantForm (see below) and Fraunhofer. [48]
  • Pharming – C1 inhibitor, human collagen 1, fibrinogen (with American Red Cross), and lactoferrin in cow milk [58] The intellectual property behind the fibrinogen project was acquired from PPL Therapeutics when PPL went bankrupt in 2004. [59]
  • Phyton Biotech uses plant cell culture systems to manufacture active pharmaceutical ingredients based on taxanes, including paclitaxel and docetaxel [60]
  • Planet Biotechnology – antibodies against Streptococcus mutans, antibodies against doxorubicin, and ICAM 1 receptor in tobacco [61]
  • PlantForm Corporation – biosimilar trastuzumab in tobacco [62] – It is developing biosimilars in collaboration with PharmaPraxis (see above) and Fraunhofer. [48]
  • ProdiGene – was developing several proteins, including aprotinin, trypsin and a veterinary TGE vaccine in corn. Was in process of launching trypsin product in 2002 [6] when later that year its field test crops contaminated conventional crops. [7] Unable to pay the $3 million cost of the cleanup, it was purchased by International Oilseed Distributors in 2003 [63] [64] International Oilseed Distributors is controlled by Harry H. Stine, [65] who owns one of the biggest soybeans genetics companies in the US. [66] ProdiGene's maize-produced trypsin, with the trademark TrypZean [67] is currently sold by Sigma-Aldritch as a research reagent. [68] [69] [70]
  • SyngentaBeta carotene in rice (this is " Golden rice 2"), which Syngenta has donated to the Golden Rice Project [71]
  • University of Arizona – Hepatitis C vaccine in potatoes [72] [73]
  • Ventria Biosciencelactoferrin and lysozyme in rice
  • Washington State University – lactoferrin and lysozyme in barley [74] [75]
  • European COST Action on Molecular Farming – COST Action FA0804 on Molecular Farming provides a pan-European coordination centre, connecting academic and government institutions and companies from 23 countries. [76] The aim of the Action is to advance the field by encouraging scientific interactions, providing expert opinion and encouraging commercial development of new products. The COST Action also provides grants allowing young scientists to visit participating laboratories across Europe for scientific training.
  • Mapp Biopharmaceutical in San Diego, California, was reported in August 2014 to be developing ZMapp, an experimental cure for the deadly Ebola virus disease. Two Americans who had been infected in Liberia were reported to be improving with the drug. ZMapp was made using antibodies produced by GM tobacco plants. [77] [78]

Projects known to be abandoned

See also

References

  1. ^ Quinion, Michael. "Molecular farming". World Wide Words. Retrieved 2008-09-11.
  2. ^ a b c d Norris, Sonya (4 July 2005). "Molecular farming". Library of Parliament. Parliament of Canada. PRB 05-09E. Retrieved 2008-09-11.
  3. ^ Humphreys, John M; Chapple, Clint (2000). "Molecular 'pharming' with plant P450s". Trends Plant Sci. 5 (7): 271–2. doi: 10.1016/S1360-1385(00)01680-0. PMID  10871897. closed access publication – behind paywall
  4. ^ Miller, Henry I. (2003). "Will we reap what biopharming sows?". Commentary. Nat. Biotechnol. 21 (5): 480–1. doi: 10.1038/nbt0503-480. PMID  12721561. closed access publication – behind paywall
  5. ^ a b c Kaiser, Jocelyn (25 April 2008). "Is the Drought Over for Pharming?" (PDF). Science. 320 (5875): 473&ndash, 5. doi: 10.1126/science.320.5875.473. PMID  18436771.
  6. ^ a b "ProdiGene Launches First Large Scale-Up Manufacturing of Recombinant Protein From Plant System" (Press release). ProdiGene. February 13, 2002. Retrieved March 8, 2013.
  7. ^ a b News of contamination[ unreliable source?]
  8. ^ Biotechnology Regulatory Services Factsheet [Internet]: US Department of Agriculture; c2006. Available from: http://www.aphis.usda.gov/publications/biotechnology/content/printable_version/BRS_FS_pharmaceutical_02-06.pdf
  9. ^ Boehm, Robert (2007). "Bioproduction of Therapeutic Proteins in the 21st Century and the Role of Plants and Plant Cells as Production Platforms". Annals of the New York Academy of Sciences. 1102: 121–34. doi: 10.1196/annals.1408.009. PMID  17470916.
  10. ^ FDA Approval News
  11. ^ a b c Ma, Julian K -C.; Barros, Eugenia; Bock, Ralph; Christou, Paul; Dale, Philip J.; Dix, Philip J.; Fischer, Rainer; Irwin, Judith; et al. (2005). "Molecular farming for new drugs and vaccines". EMBO Reports. 6 (7): 593–9. doi: 10.1038/sj.embor.7400470. PMC  1369121. PMID  15995674.
  12. ^ Houdebine, Louis-Marie (2009). "Production of pharmaceutical proteins by transgenic animals". Comparative Immunology, Microbiology and Infectious Diseases. 32 (2): 107–21. doi: 10.1016/j.cimid.2007.11.005. PMID  18243312.
  13. ^ Dove, Alan (2000). "Milking the genome for profit". Nature Biotechnology. 18 (10): 1045–8. doi: 10.1038/80231. PMID  11017040.
  14. ^ Staff (2008) FDA Approves First Human Biologic Produced by GE Animals US Food and Drug Administration, from the FDA Vetenarian Newsletter 2008 Volume XXIII, No VI, Retrieved 10 December 2012
  15. ^ "Go-ahead for 'pharmed' goat drug". BBC News. June 2, 2006. Retrieved 2006-10-25.
  16. ^ Andre Pollack for The New York Times. February 6, 2009 F.D.A. Approves Drug From Gene-Altered Goats
  17. ^ Richard H. Stern. Mayo v Prometheus: No Patents on Conventional Implementations of Natural Principles and Fundamental Truths, [2012] Eur. Intell. Prop. Rev. 502, 517. See Cochrane v. Badische Anili11 & Soda Fabrik, 111 U.S. 293, 311 (1884) (holding invalid claim to artificially made plant dye; "the product itself could not be patented, even though it was a product made artificially for the first time"); American Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. 566, 596 (1874) (holding invalid claim to artificially manufactured paper-pulp because "whatever may be said of their process for obtaining it, the product was in no sense new").
  18. ^ The American Wood-Paper case invalidated the product patent but left open the patentability of the process, saying "whatever may be said of their process for obtaining it...." 90 U.S. at 596.
  19. ^ Mayo Collaborative Services v. Prometheus Labs., Inc., 566 U.S. __, 132 S. Ct. 1289 (2012).
  20. ^ Richard H. Stern. Mayo v Prometheus: No Patents on Conventional Implementations of Natural Principles and Fundamental Truths, [2012] Eur. Intell. Prop. Rev. 502, 517-18 (quoting Mayo v. Prometheus; see also Alice v. CLS Bank, 573 U.S. __, 134 S. Ct. 2347 (2014) (to similar effect).
  21. ^ Ramessar, Koreen; Capell, Teresa; Christou, Paul (2008-02-23). "Molecular pharming in cereal crops". Phytochemistry Reviews. 7 (3): 579–592. doi: 10.1007/s11101-008-9087-3. ISSN  1568-7767.
  22. ^ Jube, Sandro; Borthakur, Dulal (2007-07-15). "Expression of bacterial genes in transgenic tobacco: methods, applications and future prospects". Electronic journal of biotechnology: EJB. 10 (3): 452–467. doi: 10.2225/vol10-issue3-fulltext-4. ISSN  0717-3458. PMC  2742426. PMID  19750137.
  23. ^ Rice, J; Mundell, Richard E; Millwood, Reginald J; Chambers, Orlando D; Stewart, C; Davies, H (2013). "Assessing the bioconfinement potential of a Nicotiana hybrid platform for use in plant molecular farming applications". BMC Biotechnology. 13 (1): 63. doi: 10.1186/1472-6750-13-63. ISSN  1472-6750. PMC  3750662. PMID  23914736.
  24. ^ Chan, Hui-Ting; Xiao, Yuhong; Weldon, William C.; Oberste, Steven M.; Chumakov, Konstantin; Daniell, Henry (2016-06-01). "Cold chain and virus-free chloroplast-made booster vaccine to confer immunity against different poliovirus serotypes". Plant Biotechnology Journal. 14 (11): 2190–2200. doi: 10.1111/pbi.12575. ISSN  1467-7644. PMC  5056803. PMID  27155248.
  25. ^ Ma, Julian K-C.; Drake, Pascal M. W.; Christou, Paul (October 2003). "The production of recombinant pharmaceutical proteins in plants". Nature Reviews Genetics. 4 (10): 794–805. doi: 10.1038/nrg1177. ISSN  1471-0056.
  26. ^ Pantaleoni, Laura; Longoni, Paolo; Ferroni, Lorenzo; Baldisserotto, Costanza; Leelavathi, Sadhu; Reddy, Vanga Siva; Pancaldi, Simonetta; Cella, Rino (2013-10-25). "Chloroplast molecular farming: efficient production of a thermostable xylanase by Nicotiana tabacum plants and long-term conservation of the recombinant enzyme". Protoplasma. 251 (3): 639–648. doi: 10.1007/s00709-013-0564-1. ISSN  0033-183X.
  27. ^ Palaniswamy, Harunipriya; Syamaladevi, Divya P.; Mohan, Chakravarthi; Philip, Anna; Petchiyappan, Anushya; Narayanan, Subramonian (2015-07-16). "Vacuolar targeting of r-proteins in sugarcane leads to higher levels of purifiable commercially equivalent recombinant proteins in cane juice". Plant Biotechnology Journal. 14 (2): 791–807. doi: 10.1111/pbi.12430. ISSN  1467-7644.
  28. ^ Imamura, Tomohiro; Sekine, Ken-Taro; Yamashita, Tetsuro; Kusano, Hiroaki; Shimada, Hiroaki (February 2016). "Production of recombinant thanatin in watery rice seeds that lack an accumulation of storage starch and proteins". Journal of Biotechnology. 219: 28–33. doi: 10.1016/j.jbiotec.2015.12.006. ISSN  0168-1656.
  29. ^ Büttner-Mainik, Annette; Parsons, Juliana; Jérôme, Hanna; Hartmann, Andrea; Lamer, Stephanie; Schaaf, Andreas; Schlosser, Andreas; Zipfel, Peter F.; Reski, Ralf (2011). "Production of biologically active recombinant human factor H in Physcomitrella". Plant Biotechnology Journal. 9 (3): 373–83. doi: 10.1111/j.1467-7652.2010.00552.x. PMID  20723134.
  30. ^ Gasdaska, John R.; Spencer, David; Dickey, Lynn (2003). "Advantages of Therapeutic Protein Production in the Aquatic Plant Lemna". BioProcessing Journal. 2 (2): 49–56. doi: 10.12665/j22.gasdaska.
  31. ^ Baur, Armin; Reski, Ralf; Gorr, Gilbert (2005). "Enhanced recovery of a secreted recombinant human growth factor using stabilizing additives and by co-expression of human serum albumin in the moss Physcomitrella patens". Plant Biotechnology Journal. 3 (3): 331–40. doi: 10.1111/j.1467-7652.2005.00127.x. PMID  17129315.
  32. ^ Cox, Kevin M; Sterling, Jason D; Regan, Jeffrey T; Gasdaska, John R; Frantz, Karen K; Peele, Charles G; Black, Amelia; Passmore, David; Moldovan-Loomis, Cristina (2006). "Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor". Nature Biotechnology. 24 (12): 1591–7. doi: 10.1038/nbt1260. PMID  17128273.
  33. ^ Decker, Eva L.; Reski, Ralf (2007). "Current achievements in the production of complex biopharmaceuticals with moss bioreactors". Bioprocess and Biosystems Engineering. 31 (1): 3–9. doi: 10.1007/s00449-007-0151-y. PMID  17701058.
  34. ^ Protalix website – technology platform Archived October 27, 2012, at the Wayback Machine.
  35. ^ Gali Weinreb and Koby Yeshayahou for Globes May 2, 2012. FDA approves Protalix Gaucher treatment Archived May 29, 2013, at the Wayback Machine.
  36. ^ a b c "Molecular Farming – Plant Bioreactors". BioPro. Archived from the original on 2011-07-18. Retrieved 2008-09-13.
  37. ^ a b Twyman, Richard M.; Stoger, Eva; Schillberg, Stefan; et al. (2003). "Molecular farming in plants: Host systems and expression technology". Trends Biotechnol. 21 (12): 570–8. doi: 10.1016/j.tibtech.2003.10.002. PMID  14624867. closed access publication – behind paywall
  38. ^ Sijmons, Peter C.; Dekker, Ben M. M.; Schrammeijer, Barbara; et al. (1990). "Production of Correctly Processed Human Serum Albumin in Transgenic Plants". Bio/Technology. 8 (3): 217–21. doi: 10.1038/nbt0390-217. PMID  1366404. closed access publication – behind paywall
  39. ^ Thomson, JA (2006). Seeds for the future: The impact of genetically modified crops on the environment. Australia: Cornell University Press.[ page needed]
  40. ^ a b c Mandel, Charles (2001-11-06). "Molecular Farming Under Fire". wired. Retrieved 2008-09-13.
  41. ^ "Protein Products for Future Global Good". molecularfarming.com. Retrieved 2008-09-11.
  42. ^ Retrieved on 15 May 2007
  43. ^ Margret Engelhard, Kristin Hagen, Felix Thiele (eds). (2007) Pharming A New Branch of Biotechnology [1]
  44. ^ Farming for Pharma
  45. ^ Fraunhofer website
  46. ^ Pharma Planta website
  47. ^ FAQ page
  48. ^ a b c Brennan, Zachary. Brazilian JV looks to tap plant-based manufacturing system for biosimilars. BioPharma-Reporter.com, 23-Jul-2014.
  49. ^ GTC website
  50. ^ Press release on opening Halle facility
  51. ^ a b Icon press release on clinical trial launch
  52. ^ Iowa State Ag School 2006 Newsletter
  53. ^ APHIS approval
  54. ^ Iowa State plant scientists tweak their biopharmaceutical corn research project
  55. ^ Kentucky Bioprocessing website
  56. ^ Vezina, Louis-P.; D'Aoust, Marc Andre; Landry, Nathalie; Couture, Manon M.J.; Charland, Nathalie; Barbeau, Brigitte; Sheldon, Andrew J. (2011). "Plants As an Innovative and Accelerated Vaccine-Manufacturing Solution". BioPharm International Supplements. 24 (5): s27–30.
  57. ^ Alfalfa page on Medicago website Archived October 1, 2012, at the Wayback Machine.
  58. ^ Company website
  59. ^ a b Press on Pharming Purchase of PPL assets
  60. ^ Phyton Biotech Official Website
  61. ^ Company website
  62. ^ Company website
  63. ^ Press release from internet archive
  64. ^ Bloomberg BusinessWeek Profile
  65. ^ http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=6741964
  66. ^ Stine Seeds Website
  67. ^ Trademark listing
  68. ^ SIgma Info Sheet
  69. ^ Ray, Kevin; Jalili, Pegah R. (2011). "Characterization of TrypZean: a Plant-Based Alternative to Bovine-Derived Trypsin (Peer-Reviewed)". BioPharm International. 24 (10): 44–8.
  70. ^ Sigma Catalog
  71. ^ FAQ page
  72. ^ [2]
  73. ^ Khamsi, Roxanne (2005). "Potatoes pack a punch against hepatitis B". News@nature. doi: 10.1038/news050214-2.
  74. ^ "NEPA Decision Summary for Permit #10-047-102r" (PDF). Animal and Plant Health Inspection Service. March 10, 2010.
  75. ^ Wettstein lab webpage
  76. ^ COST Action FA0804 Official Website
  77. ^ Ward, Andrew (8 August 2014) Biotech groups face ethical dilemmas in race for Ebola Cure, Financial Times, Page 4, Internet article retrieved 8 August 2014
  78. ^ Langreth, Robert, et al (5 August 2014) Ebola Drug Made From Tobacco Plant Saves U.S. Aid Workers Bloomberg News, Retrieved 8 August 2014
  79. ^ Published PCT Application
  80. ^ CEO Sam Huttenbauer testified before Congress in 2005 about their GM flax efforts Testimony
  81. ^ Web search on October 6, 2012, found no website for this company and found that executives are all with other companies.
  82. ^ Bloomberg BusinessWeek Profile
  83. ^ Plant production for cancer protein Sept 22, 2003
  84. ^ Press Release
  85. ^ Purchase contract
  86. ^ Press Release
  87. ^ Altor website
  88. ^ Clinical trial number NCT00879606 for "Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome" at ClinicalTrials.gov
  89. ^ Jiao, J.-a.; Kelly, A. B.; Marzec, U. M.; Nieves, E.; Acevedo, J.; Burkhardt, M.; Edwards, A.; Zhu, X.-y.; Chavaillaz, P.-A. (2009). "Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding site". Thrombosis and Haemostasis. 103 (1): 224–33. doi: 10.1160/TH09-06-0400. PMC  2927860. PMID  20062929.
  90. ^ Guardian report Sept 2001
  91. ^ Trelys press release
  92. ^ Lamb, Celia (2006-01-13). "Large Scale files Ch. 11 after closing". Sacramento Business Journal. Retrieved 2007-05-10.
  93. ^ Biomanufacturing Press Release
  94. ^ Sigma catalog Aprotinin
  95. ^ History of bankrupt biotech companies
  96. ^ Cordis entry on Novoplant
  97. ^ APHIS approval
  98. ^ Kiprijanov biography
  99. ^ UPMC buys PPL assets
  100. ^ Press release May 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on Activities

Further reading

  • Biotech firm puts off rice crop here But company says it plans to sow next year. St. Louis Post-Dispatch. April 29, 2005. Pg. A3.
  • Biotech potato provides hepatitis vaccine. The Atlanta Journal-Constitution. February 15, 2005. Pg. 3A.
  • Biotechnology Venture Hits Unexpected Snags. The New York Times. November 23, 2001. Pg. 5.
  • Canadian scientists make insulin from plants: 'Bio-pharming' poised to meet huge diabetes demand at less cost. The Ottawa Citizen. February 27, 2005. Pg. A1.
  • GM corn set to stop man spreading his seed. The Observer. September 9, 2001. Pg. 1.
  • Pharming plans transgenic first. Financial Times. May 3, 2005. Pg. 18.
  • USDA says bio-crop safeguards are tighter ProdiGene is back in Nebraska with test plot. Omaha World Herald. June 2, 2004 Pg. 01D
  • Release Permits for Pharmaceuticals, Industrials, Value Added Proteins for Human Consumption, or for Phytoremediation Granted or Pending by APHIS as of March 29, 2006. [4]

External links